Compare Stocks

3 / 10
Try these comparisons:

Stock Comparison

OPK vs PRGO vs PAHC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
OPK
OPKO Health, Inc.

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$846M
5Y Perf.-50.9%
PRGO
Perrigo Company plc

Drug Manufacturers - Specialty & Generic

HealthcareNYSE • IE
Market Cap$1.69B
5Y Perf.-77.6%
PAHC
Phibro Animal Health Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • US
Market Cap$2.38B
5Y Perf.+123.8%

OPK vs PRGO vs PAHC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
OPK logoOPK
PRGO logoPRGO
PAHC logoPAHC
IndustryMedical - Diagnostics & ResearchDrug Manufacturers - Specialty & GenericDrug Manufacturers - Specialty & Generic
Market Cap$846M$1.69B$2.38B
Revenue (TTM)$581M$4.18B$1.46B
Net Income (TTM)$-213M$-1.82B$92M
Gross Margin47.7%34.2%31.9%
Operating Margin-17.4%-4.1%11.6%
Forward P/E5.8x19.3x
Total Debt$434M$3.97B$762M
Cash & Equiv.$369M$532M$68M

OPK vs PRGO vs PAHCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

OPK
PRGO
PAHC
StockMay 20May 26Return
OPKO Health, Inc. (OPK)10049.1-50.9%
Perrigo Company plc (PRGO)10022.4-77.6%
Phibro Animal Healt… (PAHC)100223.8+123.8%

Price return only. Dividends and distributions are not included.

Quick Verdict: OPK vs PRGO vs PAHC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: PAHC leads in 4 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Perrigo Company plc is the stronger pick specifically for valuation and capital efficiency and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
OPK
OPKO Health, Inc.
The Defensive Pick

OPK is the clearest fit if your priority is sleep-well-at-night.

  • Lower volatility, beta 1.25, Low D/E 34.2%, current ratio 3.97x
Best for: sleep-well-at-night
PRGO
Perrigo Company plc
The Income Pick

PRGO is the clearest fit if your priority is income & stability and defensive.

  • Dividend streak 10 yrs, beta 1.18, yield 9.4%
  • Beta 1.18, yield 9.4%, current ratio 2.76x
  • Lower P/E (5.8x vs 19.3x)
Best for: income & stability and defensive
PAHC
Phibro Animal Health Corporation
The Growth Play

PAHC carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 27.4%, EPS growth 18.8%, 3Y rev CAGR 11.2%
  • 207.3% 10Y total return vs PRGO's -76.8%
  • 27.4% revenue growth vs OPK's -14.9%
Best for: growth exposure and long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthPAHC logoPAHC27.4% revenue growth vs OPK's -14.9%
ValuePRGO logoPRGOLower P/E (5.8x vs 19.3x)
Quality / MarginsPAHC logoPAHC6.3% margin vs PRGO's -43.5%
Stability / SafetyPRGO logoPRGOBeta 1.18 vs PAHC's 1.38, lower leverage
DividendsPRGO logoPRGO9.4% yield, 10-year raise streak, vs PAHC's 0.8%, (1 stock pays no dividend)
Momentum (1Y)PAHC logoPAHC+210.5% vs PRGO's -45.6%
Efficiency (ROA)PAHC logoPAHC6.7% ROA vs PRGO's -19.8%, ROIC 9.8% vs 3.7%

OPK vs PRGO vs PAHC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

OPKOPKO Health, Inc.
FY 2025
Service
61.0%$370M
Product
25.9%$157M
Transfer of Intellectual Property and Other
13.1%$80M
PRGOPerrigo Company plc
FY 2025
Consumer Self-Care Americas
60.8%$2.6B
Consumer Self-Care International
39.2%$1.7B
PAHCPhibro Animal Health Corporation
FY 2025
Vaccines
100.0%$137M

OPK vs PRGO vs PAHC — Financial Metrics

Side-by-side numbers across 3 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLPAHCLAGGINGOPK

Income & Cash Flow (Last 12 Months)

PAHC leads this category, winning 5 of 6 comparable metrics.

PRGO is the larger business by revenue, generating $4.2B annually — 7.2x OPK's $581M. PAHC is the more profitable business, keeping 6.3% of every revenue dollar as net income compared to PRGO's -43.5%. On growth, PAHC holds the edge at +20.9% YoY revenue growth, suggesting stronger near-term business momentum.

MetricOPK logoOPKOPKO Health, Inc.PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
RevenueTrailing 12 months$581M$4.2B$1.5B
EBITDAEarnings before interest/tax-$33M$58M$220M
Net IncomeAfter-tax profit-$213M-$1.8B$92M
Free Cash FlowCash after capex-$174M$108M$47M
Gross MarginGross profit ÷ Revenue+47.7%+34.2%+31.9%
Operating MarginEBIT ÷ Revenue-17.4%-4.1%+11.6%
Net MarginNet income ÷ Revenue-36.6%-43.5%+6.3%
FCF MarginFCF ÷ Revenue-30.0%+2.6%+3.2%
Rev. Growth (YoY)Latest quarter vs prior year-17.2%-7.2%+20.9%
EPS Growth (YoY)Latest quarter vs prior year+30.0%-56.4%+7.4%
PAHC leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

PRGO leads this category, winning 5 of 6 comparable metrics.

On an enterprise value basis, PRGO's 7.5x EV/EBITDA is more attractive than PAHC's 19.7x.

MetricOPK logoOPKOPKO Health, Inc.PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
Market CapShares × price$846M$1.7B$2.4B
Enterprise ValueMkt cap + debt − cash$910M$5.1B$3.1B
Trailing P/EPrice ÷ TTM EPS-3.73x-1.19x49.28x
Forward P/EPrice ÷ next-FY EPS est.5.82x19.33x
PEG RatioP/E ÷ EPS growth rate6.60x
EV / EBITDAEnterprise value multiple7.53x19.67x
Price / SalesMarket cap ÷ Revenue1.39x0.40x1.83x
Price / BookPrice ÷ Book value/share0.68x0.58x8.35x
Price / FCFMarket cap ÷ FCF11.63x56.82x
PRGO leads this category, winning 5 of 6 comparable metrics.

Profitability & Efficiency

PAHC leads this category, winning 6 of 9 comparable metrics.

PAHC delivers a 30.8% return on equity — every $100 of shareholder capital generates $31 in annual profit, vs $-51 for PRGO. OPK carries lower financial leverage with a 0.34x debt-to-equity ratio, signaling a more conservative balance sheet compared to PAHC's 2.67x. On the Piotroski fundamental quality scale (0–9), PAHC scores 5/9 vs OPK's 3/9, reflecting solid financial health.

MetricOPK logoOPKOPKO Health, Inc.PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
ROE (TTM)Return on equity-16.8%-50.7%+30.8%
ROA (TTM)Return on assets-11.0%-19.8%+6.7%
ROICReturn on invested capital-11.9%+3.7%+9.8%
ROCEReturn on capital employed-11.5%+4.3%+12.0%
Piotroski ScoreFundamental quality 0–9345
Debt / EquityFinancial leverage0.34x1.35x2.67x
Net DebtTotal debt minus cash$65M$3.4B$694M
Cash & Equiv.Liquid assets$369M$532M$68M
Total DebtShort + long-term debt$434M$4.0B$762M
Interest CoverageEBIT ÷ Interest expense-1.10x-7.20x3.64x
PAHC leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

PAHC leads this category, winning 6 of 6 comparable metrics.

A $10,000 investment in PAHC five years ago would be worth $23,641 today (with dividends reinvested), compared to $2,800 for OPK. Over the past 12 months, PAHC leads with a +210.5% total return vs PRGO's -45.6%. The 3-year compound annual growth rate (CAGR) favors PAHC at 61.1% vs PRGO's -24.3% — a key indicator of consistent wealth creation.

MetricOPK logoOPKOPKO Health, Inc.PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
YTD ReturnYear-to-date-11.8%-9.6%+57.5%
1-Year ReturnPast 12 months-12.5%-45.6%+210.5%
3-Year ReturnCumulative with dividends-39.8%-56.6%+318.1%
5-Year ReturnCumulative with dividends-72.0%-58.6%+136.4%
10-Year ReturnCumulative with dividends-88.5%-76.8%+207.3%
CAGR (3Y)Annualised 3-year return-15.6%-24.3%+61.1%
PAHC leads this category, winning 6 of 6 comparable metrics.

Risk & Volatility

Evenly matched — PRGO and PAHC each lead in 1 of 2 comparable metrics.

PRGO is the less volatile stock with a 1.18 beta — it tends to amplify market swings less than PAHC's 1.38 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. PAHC currently trades 97.6% from its 52-week high vs PRGO's 43.1% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricOPK logoOPKOPKO Health, Inc.PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
Beta (5Y)Sensitivity to S&P 5001.25x1.18x1.38x
52-Week HighHighest price in past year$1.60$28.44$60.08
52-Week LowLowest price in past year$0.98$9.23$18.89
% of 52W HighCurrent price vs 52-week peak+70.0%+43.1%+97.6%
RSI (14)Momentum oscillator 0–10043.253.754.5
Avg Volume (50D)Average daily shares traded2.4M3.4M273K
Evenly matched — PRGO and PAHC each lead in 1 of 2 comparable metrics.

Analyst Outlook

PRGO leads this category, winning 2 of 2 comparable metrics.

Analyst consensus: OPK as "Buy", PRGO as "Hold", PAHC as "Buy". Consensus price targets imply 156.2% upside for OPK (target: $3) vs -16.4% for PAHC (target: $49). For income investors, PRGO offers the higher dividend yield at 9.38% vs PAHC's 0.81%.

MetricOPK logoOPKOPKO Health, Inc.PRGO logoPRGOPerrigo Company p…PAHC logoPAHCPhibro Animal Hea…
Analyst RatingConsensus buy/hold/sellBuyHoldBuy
Price TargetConsensus 12-month target$2.87$20.00$49.00
# AnalystsCovering analysts133613
Dividend YieldAnnual dividend ÷ price+9.4%+0.8%
Dividend StreakConsecutive years of raises0100
Dividend / ShareAnnual DPS$1.15$0.48
Buyback YieldShare repurchases ÷ mkt cap+5.6%0.0%0.0%
PRGO leads this category, winning 2 of 2 comparable metrics.
Key Takeaway

PAHC leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). PRGO leads in 2 (Valuation Metrics, Analyst Outlook). 1 tied.

Best OverallPhibro Animal Health Corpor… (PAHC)Leads 3 of 6 categories
Loading custom metrics...

OPK vs PRGO vs PAHC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is OPK or PRGO or PAHC a better buy right now?

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus -14. 9% for OPKO Health, Inc. (OPK). Phibro Animal Health Corporation (PAHC) offers the better valuation at 49. 3x trailing P/E (19. 3x forward), making it the more compelling value choice. Analysts rate OPKO Health, Inc. (OPK) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — OPK or PRGO or PAHC?

On forward P/E, Perrigo Company plc is actually cheaper at 5.

8x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — OPK or PRGO or PAHC?

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +136.

4%, compared to -72. 0% for OPKO Health, Inc. (OPK). Over 10 years, the gap is even starker: PAHC returned +207. 3% versus OPK's -88. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — OPK or PRGO or PAHC?

By beta (market sensitivity over 5 years), Perrigo Company plc (PRGO) is the lower-risk stock at 1.

18β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 17% more volatile than PRGO relative to the S&P 500. On balance sheet safety, OPKO Health, Inc. (OPK) carries a lower debt/equity ratio of 34% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

05

Which is growing faster — OPK or PRGO or PAHC?

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus -14. 9% for OPKO Health, Inc. (OPK). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — OPK or PRGO or PAHC?

Phibro Animal Health Corporation (PAHC) is the more profitable company, earning 3.

7% net margin versus -37. 2% for OPKO Health, Inc. — meaning it keeps 3. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PAHC leads at 8. 5% versus -36. 1% for OPK. At the gross margin level — before operating expenses — PRGO leads at 35. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is OPK or PRGO or PAHC more undervalued right now?

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

8x forward P/E versus 19. 3x for Phibro Animal Health Corporation — 13. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPK: 156. 2% to $2. 87.

08

Which pays a better dividend — OPK or PRGO or PAHC?

In this comparison, PRGO (9.

4% yield), PAHC (0. 8% yield) pay a dividend. OPK does not pay a meaningful dividend and should not be held primarily for income.

09

Is OPK or PRGO or PAHC better for a retirement portfolio?

For long-horizon retirement investors, Phibro Animal Health Corporation (PAHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0.

8% yield, +207. 3% 10Y return). Both have compounded well over 10 years (PAHC: +207. 3%, OPK: -88. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between OPK and PRGO and PAHC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OPK is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; PAHC is a small-cap high-growth stock. PRGO, PAHC pay a dividend while OPK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

OPK

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 28%
Run This Screen
Stocks Like

PRGO

Income & Dividend Stock

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 20%
  • Dividend Yield > 3.7%
Run This Screen
Stocks Like

PAHC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform OPK and PRGO and PAHC on the metrics below

Revenue Growth>
%
(OPK: -17.2% · PRGO: -7.2%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.